Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs LCL 161 (Primary) ; Cyclophosphamide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 25 Aug 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Jan 2017.
    • 19 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top